Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Malignant Female Reproductive System Neoplasm × Enoxaparin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 9 Neoplasms 8 Venous Thrombosis 7 Pancreatic Neoplasms 5 Thromboembolism 4 Pulmonary Embolism 4 Thrombosis 3 Lymphoma 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Ovarian Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Hemorrhage 2 Carcinoma, Non-Small-Cell Lung 2 Venous Thormboembolism 1 Urinary Bladder Neoplasms 1 Thrombocytopenia 1 Stroke 1 Stomach Neoplasms 1 Soft Tissue Neoplasms 1 Multiple Myeloma 1 Malignant Female Reproductive System Neoplasm 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1

Interventions

Specimen Handling 2 Hydromorphone 2 palbociclib 1 neratinib 1 Palliative Care 1 Methadone 1 Mental Status and Dementia Tests 1 Magnetic Resonance Spectroscopy 1 Laparotomy 1 Interviews as Topic 1 Heparin 1 Enoxaparin 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356329 2016-05-13

Lovenox

National Guard Health Affairs

Phase 3 Suspended

Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡